Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan

Microbial Drug Resistance

Volumn 12, Issue 2, 2006, Pages 130-135

  Lau, Yeu Jun ^a   Hsueh, Po Ren ^b   Liu, Yung Ching ^c   Shyr, Jainn Ming ^d   Huang, Wen Kuei ^c   Teng, Lee Jene ^b   Liu, Cheng Yi ^e   Luh, Kwen Tay ^b  

^a SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFACLOR; CEFEPIME; CEFIXIME; CEFOTAXIME; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERTAPENEM; GATIFLOXACIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOGRAMIN DERIVATIVE; TELITHROMYCIN; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ACTIVITY; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; TAIWAN;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMASES; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HAEMOPHILUS INFLUENZAE; HOSPITALS; HUMANS; MINOCYCLINE; MORAXELLA (BRANHAMELLA) CATARRHALIS; PHENOTYPE; STREPTOCOCCUS PNEUMONIAE; TAIWAN;

HAEMOPHILUS INFLUENZAE; MORAXELLA CATARRHALIS; STREPTOCOCCUS PNEUMONIAE;

EID: 33746669944     PISSN: 10766294     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901368     Document Type: Article

References (19)

1. Batard, E., M.E. Juvin, C. Jacqueline, D. Bugnon, J. Caillon, G. Potel, and H.B. Drugeon. 2005. Influence of carbon dioxide on the MIC of telithromycin for Streptococcus pneumoniae: an in vitro-in vivo study. Antimicrob. Agents Chemother. 49:464-466.
2. Credito, K.L., G. Lin, G.A. Pankuch, S. Bajaksouzian, M.R. Jacobs, and P.C. Appelbaum. 2001. Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents. Antimicrob. Agents Chemother. 45:67-72.
3. Deshpande, L.M., A.C. Gales, and R.N. Jones. 2001. GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria. Int. J. Antimicrob. Agents. 18:29-35.
4. Drago, L., E. De Vecchi, L. Nicola, A. Colombo, and M.R. Gismondo. 2004. Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides. J. Antimicrob. Chemother. 54:542-545.
5. Peterson, LR. 2005. Antimicrobial activity and pharmacokinetics/ pharmacodynamics of the novel glycylcycline, tigecycline. Diagn. Microbiol. Infect. Dis. 52:163-164.
6. Hicks, P.S., B. Pelak, G.L. Woods, K.F. Bartizal, and M. Motyl. 2002. Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections. Clin. Microbiol. Infect. 8:753-757.
7. Hoban, D., and D. Felmingham. 2002. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J. Antimicrob. Chemother. 50(Suppl. S1):49-59.
8. Hoellman, D.B., G.A. Pankuch, M.R. Jacobs, and P.C. Appelbaum. 2000. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. 44:1085-1088.
9. Hsueh, P.R., C.Y. Liu, and K.T. Luh. 2002. Current status of antimicrobial resistance in Taiwan. Emerg. Infect. Dis. 8:132-137.
10. Hsueh, P.R., Y.C. Liu, J.M. Shyr, T.L. Wu, J.J. Yan, J.J. Wu, H.S. Leu, Y.C. Chuang, Y.J. Lau, and K.T. Luh. 2000. Multicenter surveillance of antimicrobial resistance of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan during the 1998-1999 respiratory season. Antimicrob. Agents Chemother. 44:1342-1345.
11. Hsueh, P.R., L.J. Teng, T.L. Wu, D. Yang, W.K. Huang, J.M. Shyr, Y.C. Chuang, J.H. Wan J.J. Yan, J.J. Lu, J.J. Wu, W.C. Ko, F.Y. Chang, Y.C. Yang, Y.J. Lau, Y.C. Liu, C.M. Lee, H.S. Leu, C.Y. Liu, K.T. Luh, and SMART Program 2001 Data. 2003. Telithromycin- and fluoroquinolone-resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and beta-lactams: SMART program 2001 data. Antimicrob. Agents Chemother. 47:2145-2151.
12. Hsueh, P.R., J.M. Shyr, and J.J. Wu. 2005. Decreased erythromycin consumption after antimicrobial reimbursement restriction for undocumented bacterial upper respiratory tract infections significantly reduced erythromycin resistance in Streptococcus pyogenes in Taiwan. Clin. Infect. Dis. 55:598-599.
13. Johnson, D.M., H.S. Sader, T.R. Fritsche, D.J. Biedenbach, and R.N. Jones. 2003. Susceptibility trends of Haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 47:373-376.
14. Marchese, A., L. Gualco, A.M. Schito, E.A. Debbia, and G.C. Schito. 2004. In vitro activity of ertapenem against selected respiratory pathogens. I. Antimicrob. Chemother. 54:944-951.
15. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standards, 5th edition. M7-A4. National Committee for Clinical Laboratory Standards, Wayne, PA.
16. National Committee for Clinical Laboratory Standards. 2005. Performance standards for antimicrobial susceptibility testing: thirteenth informational supplement. M100-S15 (M9). National Committee for Clinical Laboratory Standards, Wayne, PA.
17. Wexler, H.M. 2004. In vitro activity of ertapenem: review of recent studies. J. Antimicrob. Chemother. 53(Suppl. 2):ii11-ii21.
18. Zhanel, G.G., L. Palatnick, K.A. Nichol, T. Bellyou, D.E. Low, and D.J. Hoban. 2003. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1977 to 2002. Antimicrob. Agents Chemother. 47:1867-1874.
19. Zhanel, G.G., L. Palatnick, K.A. Nichol, D.E. Low, D.J. Hoban, and CROSS Study Group. 2003. Antimicrobial resistance in Haemophilus Influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 47:1875-1881.